Pharmacogenetics As a Tool to Tailor Antiretroviral Therapy: A Review

Overview

Journal World J Virol

Publisher Baishideng Publishing Group

Date 2015 Aug 18

PMID 26279982

Citations 6

Authors

Antonio Aceti

Laura Gianserra

Lara Lambiase

Alfredo Pennica

Elisabetta Teti

Affiliations

Soon will be listed here.

Abstract

Highly active antiretroviral therapy (HAART) has substantially changed human immunodeficiency virus (HIV) infection from an inexorably fatal condition into a chronic disease with a longer life expectancy. This means that HIV patients should receive antiretroviral drugs lifelong, and the problems concerning with a chronic treatment (tolerability, side effects, adherence to treatment) have now become dominant. In this context, strategies for the treatment personalization have taken a central role in optimizing the therapeutic response and prevention of adverse drug reactions. In this setting, the study of pharmacogenetics features could be a very useful tool in clinical practice; moreover, nowadays the study of genetic profiles allows optimizations in the therapeutic management of People Living With HIV (PLWH) through the use of test introduced into clinical practice and approved by international guidelines for the adverse effects prevention such as the genetic test HLA-B*5701 to detect hypersensitivity to Abacavir. For other tests further studies are needed: CYP2B6 516 G > T testing may be able to identify patients at higher risk of Central Nervous System side effects following standard dosing of Efavirenz, UGT1A1*28 testing before initiation of antiretroviral therapy containing Atazanavir may aid in identifying individuals at risk of hyperbilirubinaemia. Pharmacogenetics represents a research area with great growth potential which may be useful to guide the rational use of antiretrovirals.

Citing Articles

The role of genetic diversity, epigenetic regulation, and sex-based differences in HIV cure research: a comprehensive review.

Letchumanan P, Das K Epigenetics Chromatin. 2025; 18(1):1.

PMID: 39754177 PMC: 11697457. DOI: 10.1186/s13072-024-00564-4.

Assessment of NKG2C copy number variation in HIV-1 infection susceptibility, and considerations about the potential role of lacking receptors and virus infection.

Toson B, Michita R, Matte M, Soares R, Lawisch G, Mattevi V J Hum Genet. 2022; 67(8):475-479.

PMID: 35314764 PMC: 8938163. DOI: 10.1038/s10038-022-01029-w.

Polypharmacy in HIV: recent insights and future directions.

Edelman E, Rentsch C, Justice A Curr Opin HIV AIDS. 2019; 15(2):126-133.

PMID: 31833963 PMC: 7543953. DOI: 10.1097/COH.0000000000000608.

Characterization of Nanodiamond-based anti-HIV drug Delivery to the Brain.

Roy U, Drozd V, Durygin A, Rodriguez J, Barber P, Atluri V Sci Rep. 2018; 8(1):1603.

PMID: 29371638 PMC: 5785470. DOI: 10.1038/s41598-017-16703-9.

Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice.

Peter J, Lehloenya R, Dlamini S, Risma K, White K, Konvinse K J Allergy Clin Immunol Pract. 2017; 5(3):547-563.

PMID: 28483310 PMC: 5424615. DOI: 10.1016/j.jaip.2017.01.025.

References

Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H . Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis. 2007; 45(9):1230-7. DOI: 10.1086/522175. View

Frasco M, Mack W, van den Berg D, Aouizerat B, Anastos K, Cohen M . Underlying genetic structure impacts the association between CYP2B6 polymorphisms and response to efavirenz and nevirapine. AIDS. 2012; 26(16):2097-106. PMC: 3940150. DOI: 10.1097/QAD.0b013e3283593602. View

Hetherington S, Hughes A, Mosteller M, Shortino D, Baker K, Spreen W . Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002; 359(9312):1121-2. DOI: 10.1016/S0140-6736(02)08158-8. View

Guardiola M, Ferre R, Salazar J, Alonso-Villaverde C, Coll B, Parra S . Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation. Clin Chem. 2006; 52(10):1914-9. DOI: 10.1373/clinchem.2006.069583. View

Zanone Poma B, Riva A, Nasi M, Cicconi P, Broggini V, Lepri A . Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS. 2008; 22(14):1769-78. DOI: 10.1097/QAD.0b013e32830b3a96. View

Madeddu G, Bonfanti P, De Socio G, Carradori S, Grosso C, Marconi P . Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed Pharmacother. 2007; 62(1):6-11. DOI: 10.1016/j.biopha.2007.04.008. View

Yasuda K, Matsunaga T, Adachi T, Aoki N, Tsujimoto G, Tsuda K . Adrenergic receptor polymorphisms and autonomic nervous system function in human obesity. Trends Endocrinol Metab. 2006; 17(7):269-75. DOI: 10.1016/j.tem.2006.07.001. View

Hajeer A, Hutchinson I . Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum Immunol. 2001; 62(11):1191-9. DOI: 10.1016/s0198-8859(01)00322-6. View

Peyrieere H, Nicolas J, Siffert M, Demoly P, Hillaire-Buys D, Reynes J . Hypersensitivity related to abacavir in two members of a family. Ann Pharmacother. 2001; 35(10):1291-2. DOI: 10.1345/aph.1A022. View

10.

Wand H, Calmy A, Carey D, Samaras K, Carr A, Law M . Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS. 2007; 21(18):2445-53. DOI: 10.1097/QAD.0b013e3282efad32. View

11.

Eugen-Olsen J, Iversen A, Garred P, Koppelhus U, Pedersen C, Benfield T . Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS. 1997; 11(3):305-10. DOI: 10.1097/00002030-199703110-00007. View

12.

Hughes D, Vilar F, Ward C, Alfirevic A, Park B, Pirmohamed M . Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics. 2004; 14(6):335-42. DOI: 10.1097/00008571-200406000-00002. View

13.

Escaut L, Liotier J, Albengres E, Cheminot N, Vittecoq D . Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS. 1999; 13(11):1419-20. DOI: 10.1097/00002030-199907300-00026. View

14.

Marzolini C, Telenti A, Decosterd L, Greub G, Biollaz J, Buclin T . Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001; 15(1):71-5. DOI: 10.1097/00002030-200101050-00011. View

15.

Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S . Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis. 2006; 43(1):99-102. DOI: 10.1086/504874. View

16.

Costarelli S, Torti C, Benerini Gatta L, Tinelli C, Lapadula G, Quiros-Roldan E . No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients. J Acquir Immune Defic Syndr. 2007; 46(2):255-6. DOI: 10.1097/QAI.0b013e3180ed44d9. View

17.

Baylor M, Johann-Liang R . Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr. 2004; 35(5):538-9. DOI: 10.1097/00126334-200404150-00014. View

18.

Safrin S, Grunfeld C . Fat distribution and metabolic changes in patients with HIV infection. AIDS. 2000; 13(18):2493-505. DOI: 10.1097/00002030-199912240-00002. View

19.

Ribaudo H, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif A . Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis. 2010; 202(5):717-22. PMC: 2919241. DOI: 10.1086/655470. View

20.

Monaghan G, Ryan M, Seddon R, HUME R, Burchell B . Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet. 1996; 347(9001):578-81. DOI: 10.1016/s0140-6736(96)91273-8. View